|
|
|
|
|
|
|
|
|
19.04.26 - 05:00
|
Will AI job fears hurt China′s housing market as they have in the US and India? (SCMP)
|
|
|
Growing public anxiety over artificial intelligence-driven job loss, especially in technology and other white-collar sectors, has weighed on housing sentiment in the US and India.
Yet data remains insufficient to quantify the direct impact of AI-related job fears on China's sluggish home-buying sentiment, though analysts expect such concerns to make households more cautious about long-term housing purchase decisions.
China's rapid AI adoption to boost automation and productivity had implications......
|
|
|
19.04.26 - 03:06
|
AI is not eating up China′s software market but turbocharging it: HSBC analyst (SCMP)
|
|
|
China's artificial intelligence model companies are unlikely to “eat up” the domestic software market because they lack the deep industry know-how and experience to meet enterprise needs, according to an HSBC analyst.
Unlike the US, China's less developed software-as-a-service (SaaS) market stands to gain even as AI models continue to improve, with the most likely outcome being a collaborative approach where model companies and legacy software firms serve enterprises in tandem, said Yiran Liu,......
|
|
|
|
|
|
|
|
|
|
|
|
|
18.04.26 - 10:06
|
Huawei retains lead in China smartphone market, Apple shipments surge in first quarter (SCMP)
|
|
|
Huawei Technologies claimed the top spot in China's smartphone market in the first quarter with its highest share in five years, while Apple saw the strongest growth among the top six players, despite a global memory chip crunch.
Huawei held a 20 per cent share in the first three months, the highest since the fourth quarter of 2020, according to a Friday report by Counterpoint Research. Chinese government subsidies that offered a 15 per cent discount for gadgets under 6,000 yuan (US$880), along......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.04.26 - 05:00
|
As China′s biotech firms shift gears, can AI floor the accelerator? (SCMP)
|
|
|
A quarter featuring multiple eye-popping deals is no longer unusual for China's pharmaceutical industry – in fact, it may soon be considered a slow season.
In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million.
Under the terms of the deal, the Beijing-based Haisco granted US......
|
|
|
|
|
|
Top- News zu China 15546.102 +0.66% (China A50 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
